effect of angiotensin converting enzyme inhibitors on left ventricular remodelling after infarction, because they combined afterload reduction with the potentially useful blocking action on neurohormonal activation, including direct effects upon angiotensin II and indirect effects on noradrenaline and vasopressin.
Use of ACE inhibitors: load reduction and neurohormonal blockade Pfeffer and colleagues first demonstrated in the rat that early and continued captopril treatment significantly improved survival provided that the myocardial infarction involved less than 50% of the left ventricle. 2324 The mechanism proposed to explain this finding was that angiotensin converting enzyme inhibition with captopril prevented progressive left ventricular dilatation and the development of heart failure. Studies were subsequently performed in humans to determine whether captopril lessened left ventricular enlargement after acute myocardial infarction and improved functional capacity compared with placebo,25 and whether the combination of captopril and thrombolysis conferred additional benefit over and above that derived from thrombolysis alone.2627 Though early placebo controlled post-infarction trials with captopril contained only small patient cohorts, they consistently showed that captopril lessened progressive left ventricular dilatation and improved ejection fraction compared with placebo, and these effects were maintained after the drug was stopped. 34 The SAVE trial was a placebo controlled, double blind, randomised trial in which the primary objectives were to determine whether captopril reduced mortality and improved the clinical outcome of survivors of acute myocardial infarction who had left ventricular dysfunction at baseline (defined as an ejection fraction of <40%) but no overt heart failure and no ongoing myocardial ischaemia. 30 The predefined clinical end points were cardiovascular mortality, deterioration in left ventricular function, severe heart failure requiring admission to hospital, severe heart failure which despite digitalis and diuretics required open-label ACE inhibition, and recurrent myocardial infarction.'0 SAVE differed from other post-infarction trials in several important respects: baseline left ventricular ejection fraction was < 40%, randomisation to treatment assignment was between three and 16 days (mean 11 days) after infarction, study medication (captopril or placebo) was titrated to 50 mg three times a day and continued over a minimum of two and a mean of three years follow up. The SAVE trial is the first and so far the only trial to show that angiotensin-converting enzyme inhibition with captopril, started early and continued long-term, significantly reduces (21 %) cardiovascular mortality compared with placebo. 30 The difference in survival between the captopril and the placebo treated patients only emerged at 10 months, but thereafter became increasingly more apparent with longer follow up. Importantly, the favourable impact upon mortality in survivors of acute myocardial infarction depended on the prolonged and continuous use of ACE inhibitors. The incidence of congestive heart failure requiring admission to hospital or open-label ACE inhibitors in addition to digitalis and diuretics increased with time, but was significantly less common in the patients randomly assigned to treatment with captopril. Captopril reduced the risk of development of progressive heart failure by 36%, the risk of fatal or non-fatal re-infarction by 25%, and the risk of cardiovascular death or major adverse cardiovascular event by 24% compared with placebo.30 There was a similar reduction in the combined end points of cardiovascular death and heart failure by zofenopril in SMILE. ' provided in the SAVE echocardiographic substudy35 and by previous studies. 26 28 29 Secondly, partial inhibition of the activation of circulating neurohormones, for example renin-angiotensin, noradrenaline and atrial natriuretic peptide. Perhaps the combination of these interacting mechanisms accounts for the increase in ejection fraction and improved left ventricular diastolic function because the beneficial effects of captopril on the latter appear to be independent of ventricular dilatation. 36 The CONSENSUS II trial also investigated the effect of ACE inhibition on mortality and adverse cardiovascular events after acute myocardial infarction, but differed from SAVE in three major respects." First, enlapril rather than captopril was used. Secondly, all patients with myocardial infarctions regardless of infarct size, location, transmurality, and baseline ventricular function were elegible for enrolment. Thirdly, enalapril was administered intravenously within 24 hours of infarction. CONSENSUS II enrolled more than 6000 patients, but in contrast to SAVE did not show any beneficial effects on cardiovascular mortality or recurrent myocardial infarction." CONSENSUS II was terminated prematurely because lifetable mortality rates at one and six months showed no difference between the patients randomly assigned to enalapril or to placebo, and also early hypotensive episodes occurred more frequently in the patients treated 
